Dopamine agonist vs placebo
Withdrawals due to adverse events · patients with restless legs syndrome according to IRLSSG, 18 years or older
Summary of findings: dopamine agonists leads to higher number of dropouts due to adverse events compared with placebo (high certainty).
1 finding from 1 review
- Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes onlyOR 1.82 [1.35, 2.45]34 studies · 7054 participantsHigh